Recent Research Funding

Tom Russo and Tim Umland.

More than $2 million in annual extramural funding goes to researchers in our division, including Thomas Russo, MD, (left), shown with collaborator Timothy C. Umland, PhD.

Faculty research is supported by extramural funding of more than $2 million annually. The majority of support is derived from national funding agencies such the National Institutes of Health, the Department of Defense and the Veterans Administration.

John Crane, MD, PhD

  • SOS Response as a Generator of Antibiotic Resistance and Role of Zinc as SOS Inhibitor. John Crane (Principal Investigator). National Institutes of Health. $444,325. 6/1/2019-5/1/2021.

Timothy Murphy, MD

  • Genome Evolution During Bacterial Persistence in the Human Airways in COPD. Timothy Murphy (Principal Investigator). NIAID. $2,653,298. 7/1/2019-6/1/2024.
  • Training the Next Generation of Physician Scientists T35 Training Grant. Timothy Murphy (Principal Investigator). NIAID. $242,416. 9/1/2016-6/1/2021.
  • National Center for Advancing Translational Sciences. Timothy Murphy (Principal Investigator), John Canty, Jr. (Contributor). NIH. 9/1/2015-6/1/2020.
  • Clinical and Translational Science Award: Buffalo Clinical and Translational Research Center. Timothy Murphy (Principal Investigator), Margarita Dubocovich (Co-Investigator), Gene Morse (Co-Investigator), Barry Smith (Co-Investigator). National Center for Advancing Translational Sciences. $13,151,902. 8/1/2015-3/1/2019.
  • Persistent H.influenzae in COPD: virulence, vaccines, and antibiotic resistance. Timothy Murphy (Principal Investigator). NIAID. $2,456,267. 9/1/2014-8/1/2018.

Thomas Russo, MD

  • Identification of new or unrecognized virulence genes in hypervirulent Klebsiella pneumoniae and antivirulence genes in classical K. pneumoniae. Thomas Russo (Principal Investigator). NIH. $431,682. 8/1/2020-7/1/2022.
  • Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannii. Thomas Russo (Principal Investigator). Veterans Administration. $699,244. 10/1/2019-9/1/2023.
  • DHODH Inhibitors: A Potential New Class of Antimicrobials for Treatment of the Drug Resistant Gram-Negative Bacillus Acinetobacter baumannii. Thomas Russo (Co-Principal Investigator). NIH/NIAID. $981,697. 8/1/2018-8/1/2021.
  • Mab Passive Vaccination against Acinetobacter baumannii. Thomas Russo (Co-Investigator). NIH. $491,635. 9/1/2017-8/1/2022.
  • Development of a diagnostic test for hypervirulent Klebsiella pneumoniae. Thomas Russo (Principal Investigator). NIH. $438,625. 3/1/2016-2/1/2019.
  • Development of HTP Assay for Inhibitors of Aerobactin Production(R01AI116998). Thomas Russo (Co-Investigator), Andrew Gulick (Principal Investigator). National Institutes of Health. 2/1/2016-1/1/2019.
  • Development of a HTP Assay for Inhibitors of Aerobactin Production. Thomas Russo (Co-Investigator). NIH. $358,875. 2/1/2016-1/1/2020.

Brahm Segal, MD

  • A CRISPR-based platform for testing neutrophil responses in the ovarian cancer microenvironment (3R01CA188900-05W1). Brahm Segal (Principal Investigator). NCI. $207,918. 8/1/2019-5/1/2020.
  • The Mae Stone Goode Charitable Trust. Brahm Segal (Co-Principal Investigator), Thomas Cimato (Principal Investigator). $100,000. 3/1/2016-3/1/2019.
  • Evaluation of HSCs and MSCs in ovarian cancer (PI: Dr. Thomas Cimato). Brahm Segal (Co-Investigator). Mae Stone Trust. $100,000. 3/1/2016-3/1/2018.
  • Novel Immunological Biomarkers in Ovarian Cancer Prognosis. Brahm Segal (Principal Investigator). NIH. $3,148,229. 6/1/2015-5/1/2020.